Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation, announced on Oct. 31, 2022 that it is expanding its contract development and manufacturing services for parenteral drugs to customers outside of Japan. The contract and development manufacturing organization (CDMO) offers end-to-end services with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for biotech drugs and small molecules.
Lakewwod, Colorado, US, September 19, 2022 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announces the launch of its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo BCT identified the industry’s need for earlier automation to potentially limit additional and time-consuming steps such as bridging studies and technology transfers. Quantum Flex allows developers to complete their early process development on the same platform they will use for manufacturing, creating a cell culture environment where cells thrive. Early process development may lead to reduced cost and risk of unanticipated process deviations in later phases of clinical trials.
Terumo Blood and Cell Technologies and BioBridge Global subsidiary, GenCure, have entered a new partnership agreement to expand and integrate cell and gene therapy manufacturing solutions.
Market Place
Share
Share
